Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Trial of Everolimus and Letrozole or Hormonal Therapy (Tamoxifen/Medroxyprogesterone Acetate) in Women With Advanced, Recurrent, or Persistent Endometria Carcinoma

NCT02228681 is registered in ClinicalTrials.gov with GOG Foundation as lead sponsor.

NCT NCT02228681
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02228681 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Trial of Everolimus and Letrozole or Hormonal Therapy (Tamoxifen/Medroxyprogesterone Acetate) in Women With Advanced, Recurrent, or Persistent Endometria Carcinoma
Lead sponsor
GOG Foundation
Phase
Phase 2
Overall status
Completed
Start date
May 21, 2015
Completion date
August 22, 2024
Enrollment
74 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

advanced, persistent, or recurrent endometrial cancer